MorphoSys AG buy Maxi_Scalibusa
Summary
This prediction ended on 11.04.11 with a price of €18.81. With a performance of -2.29%, the BUY prediction for MorphoSys AG by Maxi_Scalibusa closed slightly in the red. Maxi_Scalibusa has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | 2.219% | 2.219% | 225.695% | -5.356% |
| iShares Core DAX® | 2.831% | 1.236% | 14.788% | 17.647% |
| iShares Nasdaq 100 | 2.918% | 0.640% | 40.290% | 50.762% |
| iShares Nikkei 225® | 2.007% | -2.135% | 19.861% | 4.937% |
| iShares S&P 500 | 2.257% | 0.451% | 30.090% | 43.940% |
Comments by Maxi_Scalibusa for this prediction
In the thread Morphosys AG diskutieren
Chart sagt kaufen
Interessante Chartsituation. Die Aktie kämpf derzeit mit den Jahreshochs der Vorjahre, aber wie sie das macht ist interessant. Vor kurzem Rückläufer an den Asubruch der langen Seitwärtsphase und nun lange Hammer-Kerze. 1. Position bereits jetzt interessant, Aufstockung bei Überwindung des letzten Hochs.